New combo therapy aims to shrink rare melanoma before surgery
NCT ID NCT07517653
First seen Apr 16, 2026 · Last updated May 19, 2026 · Updated 7 times
Summary
This study tests whether giving two drugs (SHR-1701 and famitinib) before surgery can improve outcomes for people with a rare and aggressive skin cancer called mucosal melanoma. After surgery, treatment is tailored based on how well the tumor responded. The trial involves 70 adults whose cancer can be completely removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.